Nascent Biotech, Inc. (OTCMKTS:NBIO) Short Interest Down 99.3% in November

Nascent Biotech, Inc. (OTCMKTS:NBIO) saw a significant drop in short interest in the month of November. As of November 30th, there was short interest totalling 100 shares, a drop of 99.3% from the November 15th total of 13,900 shares. Based on an average daily volume of 41,800 shares, the short-interest ratio is presently 0.0 days.

Nascent Biotech Stock Performance

Nascent Biotech stock remained flat at $0.05 during trading hours on Friday. Nascent Biotech has a 12-month low of $0.03 and a 12-month high of $0.22. The firm has a fifty day simple moving average of $0.06 and a 200 day simple moving average of $0.06.

Nascent Biotech Company Profile

Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.